AstraZeneca to pay up to $4.1bn for BMS share of diabetes JV
This article was originally published in Scrip
AstraZeneca is acquiring Bristol-Myers Squibb's share of their global diabetes alliance assets for $2.7bn up front and up to a further $1.4bn in regulatory, launch and sales-related payments.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.